Inactive Instrument

NeoStem Inc Stock price Nyse

Equities

NBS

US6406503051

Biotechnology & Medical Research

End-of-day quote Nyse
- USD 0.00% Intraday chart for NeoStem Inc
Sales 2024 * - Sales 2025 * - Capitalization 25.92M
Net income 2024 * -25M Net income 2025 * -30M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.01 x
P/E ratio 2025 *
-1.16 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81%
More Fundamentals * Assessed data
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug MT
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme CI
Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma CI
Transcript : Lisata Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents CI
Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1 CI
Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma CI
Transcript : Lisata Therapeutics, Inc., Q2 2023 Earnings Call, Aug 15, 2023
Lisata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lisata Therapeutics' LSTA1 Malignant Glioma Treatment Candidate Gets FDA Orphan Drug Label MT
More news
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
More about the company